post-bg-587
calendary January 16, 2023

New HIV drug approved in Europe

On June 23, 2022, an innovative HIV drug called Sunlenca (lenacapavir) manufactured by the American company Gilead was approved in Europe. The drug has been approved under a centralized procedure in all 27 EU member states, including Norway, Iceland and Liechtenstein.

The regulators made their decision based on a phase II/III study called CAPELLA. In the trial, 83 % of patients treated with lenacapavir in addition to an optimized background regimen achieved an undetectable viral load (<50 copies/mL) at week 52. Phase III trials are currently underway to use the agent as pre-exposure prophylaxis, as well as phase II trials to test the drug in people who have never received HIV therapy before.

Sunlenca is a capsid inhibitor indicated for the treatment of multidrug-resistant HIV infection in adults. The advantage of the drug is not only its high efficiency, but also the frequency of administration: in clinical trials, Sunlenca was administered to participants only 2 times a year in combination with other antiretroviral drugs. The data obtained indicated high rates of virological suppression in people with HIV who had previously received therapy.

Lenacapavir also showed good tolerability and did not cause serious adverse events. The most commonly observed adverse events were reactions at the injection site.

The drug is manufactured in two dosage forms - tablets and solution for injection. According to the instructions for use, treatment begins with taking a tablet form, then patients switch to injections.

Interestingly, in the US, the Food and Drug Administration (FDA) rejected Gilead's new drug application (NDA) for lenacapavir due to manufacturing problems, namely the formation of glass particles from the interaction of Sunlenca and borosilicate vials for the drug. The application was resubmitted in July 2022 and is currently under review by the regulator.

It is worth noting that Sunlenca is not the first injectable drug for the treatment of HIV infection, designed to reduce the frequency of administration. In 2021, FDA approved an injectable HIV treatment called Cabenuva from ViiV Healthcare. The drug, consisting of the active substances cabotegravir and rilpivirine, must be administered every month to suppress the virus. It has been proven that injection and tablet methods of treating HIV are equally effective.

References:
  1. http://publication.pravo.gov.ru/Document/View/0001202212220041
  2. http://www.consultant.ru/document/cons_doc_LAW_186846/

More related posts

new-img-1

Control

Fine for spa resort in Yessentuki

Roszdravnadzor has imposed a fine of 130 thousand rubles on a spa resort in Yessentuki for improper storage of medical products…

03.03.2016
READ ARTICLE
new-img-2

Roszdravnadzor

Roszdravnadzor – patients’ rights

In 2015, Roszdravnadzor restored the rights of more than 460 thousand citizens to effective, accessible, and safe medical…

03.03.2016
READ ARTICLE
new-img-3

Regulation

The certification scheme for medical products hasn’t changed recently

Roszdravnadzor informs that the certification scheme for products in the Russian Federation is determined by Decree of the…

03.04.2016
READ ARTICLE
new-img-4

Control

Fines – Rostov region

In one and a half months of 2016, the Local Agency of Roszdravnadzor in Rostov Region imposed fines of the total amount of…

03.10.2016
READ ARTICLE
new-img-5

Control

Unregistered medical products

Two citizens were fined for selling unregistered medicinal products on the Internet in the Republic of Bashkortostan.

03.10.2016
READ ARTICLE
new-img-6

Control

Unscheduled inspection by roszdravnadzor

Roszdravnadzor started an unscheduled inspection of the Federal State-Funded Institution of Sverdlovsk Region Kirovgrad Central…

03.14.2016
READ ARTICLE
new-img-7

Medical Devices

International medical device regulators forum (IMDRF)

The delegation of the Federal Service for Surveillance in Healthcare headed by Mikhail Murashko, Head of Roszdravnadzor,…

03.17.2016
READ ARTICLE
new-img-8

Pharmaceuticals

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF”

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF” in which pills the metal wire was found.

05.18.2016
READ ARTICLE
new-img-9

Roszdravnadzor

Medical equipment stands idle in the Pskov region

Roszdravnadzor (RZN) statement: the expensive medical equipment for the total amount of 342 million rubles stands idle in…

05.19.2016
READ ARTICLE
new-img-10

Control

Hospital control Jewish autonomous region

Roszdravnadzor has audited the activity of the Regional Budgetary Public Health Facility “Central district hospital of Lenin”…

05.20.2016
READ ARTICLE